Press Releases

 
Press Releases
  Date Title View
Aug 30, 2016
ALBANY, N.Y., Aug. 30, 2016 /PRNewswire/ -- Albany Molecular Research Inc. (NASDAQ: AMRI) announced today that William S. Marth, AMRI's President and Chief Executive Officer, will present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016 at 3:30 p.m. ET. A live audio webcast of the presentation can be accessed at AMR...
Aug 24, 2016
ALBANY, N.Y., Aug. 24, 2016 /PRNewswire/ -- Albany Molecular Research Inc. (NASDAQ: AMRI) announced today that William S. Marth, AMRI's President and Chief Executive Officer, will present at the Baird 2016 Global Healthcare Conference on Wednesday, September 7, 2016 at 1:25 p.m. ET. A live audio webcast of the presentation can be accessed at AMRI's...
Aug 23, 2016
ALBANY, N.Y., Aug. 23, 2016 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that it entered into a non-exclusive commercial license agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9 gene editing technology and has completed several projects for its customers. The company will continue to use the technology to enha...
Aug 4, 2016
ALBANY, N.Y., Aug. 4, 2016 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today reported financial and operating results for the second quarter ended June 30, 2016 and provided an update to its outlook for 2016. Highlights: Contract revenue of $116.5 million, up 37% from the second quarter 2015 Recurring royalty revenue of $4.4 million ...
Jul 15, 2016
ALBANY, N.Y., July 15, 2016 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced it will issue second quarter 2016 financial results before the opening of the market on Thursday, August 4, 2016.  Following the release of its results, the company will host a conference call and simultaneous audio webcast at 8:30 a.m. ET. The conference call ca...
Jul 11, 2016
ALBANY, N.Y., July 11, 2016 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that it has completed the acquisition of Prime European Therapeuticals S.p.A., also known as "Euticals", a privately-held company headquartered in Lodi, Italy, specializing in custom synthesis and the manufacture of active pharmaceutical ingredients (APIs). This complet...
Jun 22, 2016
TAMPA, Fla. and ALBANY, N.Y., June 22, 2016 /PRNewswire/ -- Teewinot Life Sciences Corporation (Teewinot) and Albany Molecular Research, Inc. (NASDAQ: AMRI) today announced that AMRI has licensed Teewinot's technology to produce and sell the first commercially available cannabichromene acid (CBCA) analytical standard. The CBCA analytical standard i...
Jun 14, 2016
ALBANY, N.Y., June 14, 2016 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that its Buffalo, N.Y. site has been selected to participate as a Dedicated Chemical Biology Consortium  (CBC) Center for the Experimental Therapeutics (NExT) Program, centered at the Frederick National Laboratory for Cancer Research. The Frederick National Lab,...
May 23, 2016
ALBANY, N.Y., May 23, 2016 /PRNewswire/ -- Albany Molecular Research Inc. (NASDAQ: AMRI) announced today that William S. Marth, AMRI's President and Chief Executive Officer, will present at Jefferies 2016 Healthcare Conference on Tuesday, June 7, 2016 at 3:30 p.m. ET. A live audio webcast of the presentation can be accessed at AMRI's Investor Relat...
May 10, 2016
ALBANY, N.Y., May 10, 2016 /PRNewswire/ -- AMRI (NASDAQ: AMRI) clarified its 2016 revenue guidance, following the company's first quarter earnings conference call held earlier this morning. The company expects approximately 50% of its 2016 revenue to be realized in the first half of the year and the corresponding 50% in the second half of th...
Page:
1
... NextLast
= add release to Briefcase